Evidence-Based Complementary and Alternative Medicine / 2021 / Article / Tab 2 / Review Article
Xueshuantong Injection in Treating Deep Venous Thrombosis: A Systematic Review and Trial Sequential Analysis Table 2 Characteristics of the included studies.
Included study Sample size (T/C) Treatment Gender (M/F) Age (years) Treatment course (days) Random method Evaluation indicators Experimental group Control group Experimental group Control group Experimental group Control group Yang Xi, 2020 [9 ] 20/29 Xueshuantong injection + low molecular weight heparin Low molecular weight heparin 0/20 0/29 56.45 ± 19.74 57.05 ± 21.74 14 Random number table 7;8;9 Lan Jinyao, 2019 [10 ] 91/91 Xueshuantong injection + low molecular weight heparin Low molecular weight heparin 50/41 42/49 51.72 ± 16.82 48.73 ± 18.27 14 Random number table 1;7;9 Pei Guanghua, 2019 [11 ] 36/36 Xueshuantong injection + urokinase injection Urokinase injection 20/16 21/15 62.9 ± 1.1 62.8 ± 1.2 14 Random number table 1;2;3;4 Shi Yiwen, 2019 [12 ] 38/38 Xueshuantong injection + rivaroxaban Rivaroxaban 45/31 57.7 ± 4.5 14 Drawing lots 1;5;6 Wang Xiaobo, 2019 [13 ] 42/42 Xueshuantong injection + urokinase injection Urokinase injection 27/15 25/17 68.7 ± 5.5 68.3 ± 5.6 14 — 2;3;4 Xu Chunyu, 2019 [14 ] 45/45 Xueshuantong injection + urokinase injection + low molecular weight heparin Urokinase injection + low molecular weight heparin 25/20 24/21 59.12 ± 6.34 58.49 ± 6.28 14 Random number table 5;6;8 Chen Kui, 2018 [15 ] 34/34 Xueshuantong injection + urokinase injection + low molecular weight heparin Urokinase injection + low molecular weight heparin 19/15 18/16 53.96 ± 18.95 54.14 ± 19.02 14 Admission sequence 1; 5;6;7;8 Pan Lei, 2018 [16 ] 63/63 Xueshuantong injection + rivaroxaban Rivaroxaban 32/31 33/30 65.09 ± 4.12 65.24 ± 4.27 14 Random number table 1;7;9 Zhang Yanwen, 2018 [17 ] 25/25 Xueshuantong injection + low molecular weight heparin Low molecular weight heparin 14/11 15/10 67.83 ± 7.24 67.19 ± 6.25 14 — 1;7;8;9 Zhou Bo, 2015 [18 ] 44/43 Xueshuantong injection + low molecular weight heparin + warfarin Low molecular weight heparin + warfarin 30/14 29/14 64.3 ± 5.2 64.8 ± 5.5 10 — 1;8 Zhou Yuhu, 2015 [19 ] 39/39 Xueshuantong injection + rivaroxaban Rivaroxaban 21/18 20/19 66.52 ± 3.63 66.61 ± 3.72 14 — 1;5;6;7;8;9 Zhang Jianping, 2012 [20 ] 28/28 Xueshuantong injection + urokinase injection + low molecular weight heparin + aspirin Urokinase injection + low molecular weight heparin + aspirin 18/10 15/13 57.25 ± 13.64 55.31 ± 14.26 14 Random number table 2;3;4;9
Note. ① Clinical efficiency. ② Patency rate of femoral vein. ③ Patency rate of the popliteal vein. ④ Patency rate of the posterior tibial vein. ⑤ Circumference difference of upper knee limb. ⑥ Circumference difference of lower knee limb. ⑦ APTT. ⑧ D-D. ⑨ Incidence of adverse events.